People misused opioids in 2019. 886K
used heroin. 562K misused both pain
relievers and heroin3
Home › About ›
There is a great demand and an unmet need for an effective, long acting, local non-opiate pain relief product.
Opioid abuse and addiction have reached epidemic proportions in the US. The CDC reports that in 2018, approximately 70,000 people died from drug overdose in the US alone. Most of these deaths were in adults between the ages of 25 and 54 years old which should be their prime productive years. The economic cost of prescription opioid-related overdose, abuse and dependence exceeds $78.5 billion annually with the majority of costs related to health care, substance abuse treatment, and lost productivity (Med Care. October 2016;54(10):901–906.)
The only US marketed non-opiate extended relief post-surgical topical product suffers from several shortcomings from high production cost to fragility and the need for careful handling. Moreover, the physical characteristics of this product require multiple injections which is a burdensome task to the surgeon. In comparison, PRF-110 is based on a simple, easy to manufacture formulation and is simply applied into the wound, prior to suturing.
People misused opioids in 2019. 886K
used heroin. 562K misused both pain
relievers and heroin3
People have an opioid use disorder. 1.7
million people with a prescription pain
reliever have a use disorder.3
Of people listed pain as their main reason
for opioid misuse where 36% of people
with an opioid problem received a
prescription from a healthcare provider3
Per year US economic burden where
40,000 people a year die from opioid
related issues2